Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Catalent Inc Shares Rise 13%

Published 08/29/2017, 09:23 AM
Updated 03/09/2019, 08:30 AM

Catalent Inc (NYSE:CTLT) shares jumped by as much as 13.12% on Monday’s trading session after the company posted an upbeat fourth quarter and full year earnings report for the year 2017 that beat most analyst estimates.

The New Jersey-based company is known for being a delivery technologies and development solutions provider for biologics and consumer products, animal health products, and drugs. For the fourth quarter, the company posted an adjusted earnings if $0.65 on a revenue of $616.90 million beating most analysts forecasts by $0.08 per share. The revenue was also $67 million higher than most analyst estimates.

The earnings represent a jump of 16% in their quarterly earnings and 19% rise in constant currency from $532.2 million during the same quarter last year. Catalent Inc fourth quarter net earnings for the year came in at $61.8 million or around $0.49 per diluted share. This is versus the net income during the same period last year of $58.1 million or $0.46 per diluted share.

The company’s total revenue for the fiscal year 2017 came in 12% higher at $2.075 billion. However, their fiscal year net earnings were slightly lower compared to last year at $0.89 per diluted share to this year’s $0.87 per diluted share.

Catalent’s revenue from their Softel Technologies business jumped by 14% for the fourth fiscal quarter to $257.1 million compared to the same quarter a year ago. The growth of their revenue for this sector was attributed by the company to the higher end market demand in Europe for prescription products. For the whole year, Softgel Technologies segment revenue came at $855.3 million for the whole fiscal year which represents a jump of 10%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The company also experienced a rise in the demand for both prescription products and consumer health products in North America that help reduce renewed demand for lower-end market demand for consumer health products in Asia Pacific.

The revenue of the company from their Clinical Supply Services business has also jumped by 22% from last year’s fourth quarter to $99.3 million. The growth was attributed to core storage, distribution, and manufacturing and packaging services’ higher volume and the rise of lower margin comparator sourcing activities.

Latest comments

m'l so great and you
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.